中泰国际发研报指, 联邦制药 (03933)2025年上半年收入同比增加4.8%至75.2亿元(人民币,下同),股东净利润同比增加27.0%至18.9亿元,但如剔除与诺和诺德(NVOUS)授权协议获取的14.3亿元首付款外,公司的产品销售收入及盈利逊于市场及该机构的预期。分板块看,制剂板块的产品销售收入同比增加6.1%至25.4亿元,但中间体与 原料药 收入分别同比下降23.1%与27.0%。制剂...
Source Link中泰国际发研报指, 联邦制药 (03933)2025年上半年收入同比增加4.8%至75.2亿元(人民币,下同),股东净利润同比增加27.0%至18.9亿元,但如剔除与诺和诺德(NVOUS)授权协议获取的14.3亿元首付款外,公司的产品销售收入及盈利逊于市场及该机构的预期。分板块看,制剂板块的产品销售收入同比增加6.1%至25.4亿元,但中间体与 原料药 收入分别同比下降23.1%与27.0%。制剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.